Lactoferrin and skin

Two reviews have tried to summarize what lactoferrin does to skin. The earlier one searched PubMed and Embase for clinical studies in any dermatological condition and found six. Its authors, a dermatology department at the University of California, Davis, reported encouraging signs in acne, psoriasis and diabetic ulceration, and wrote that further research was needed before lactoferrin could be called a complementary therapy. The second review, published in 2026 by a hospital dermatology department in Shanghai, covered melanoma, acne, psoriasis and wound healing, and put the position more bluntly: the available evidence comes mainly from cell culture and animal models, and the clinical evidence remains limited.

Six is a small literature for a protein sold by the gram for skin, and two more controlled studies have appeared since that search. The more useful question is how many of them gave lactoferrin on its own, because a capsule holding four ingredients cannot tell anyone which ingredient worked.

What each study actually administered

Figures come from each study's own abstract. These seven are the controlled studies of lactoferrin in a skin condition that this page could identify. They overlap with the six counted in the 2017 review without being the same set, since that review searched before the later entries here appeared. The fourth column is the one that matters, and in four of the seven rows it is not empty.

The one acne trial that isolated the protein

Kim and colleagues randomized adults aged 18 to 30 with acne vulgaris to fermented milk containing 200 mg of lactoferrin a day, or to the same fermented milk without it, for twelve weeks, double-blind. Eighteen people were assigned to each arm. Because both arms drank the same fermented milk, lactoferrin was the only difference between them, which is what makes this trial worth more than its size suggests.

At twelve weeks the lactoferrin group had 38.6% fewer inflammatory lesions, 23.1% fewer lesions in total and an acne grade 20.3% lower than the control group. Sebum content fell by 31.1%. The trial also measured skin surface lipids and found that triacylglycerols and free fatty acids both decreased on lactoferrin while only free fatty acids decreased on the control milk, and that the fall in triacylglycerols correlated with the falls in sebum, lesion count and acne grade. The authors concluded that the protein improves acne through a selective decrease in triacylglycerols.

Thirty-six participants is a small trial, and twelve weeks is a short one. No replication of that design appears in either systematic review, or in the searches behind this page, in the sixteen years since.

What the same trial measured and did not find

Kim's team recorded skin hydration and skin surface pH alongside the acne outcomes, at baseline and at twelve weeks. Neither changed, in either group.

Hydration and pH are instrument readings that describe skin without reference to any particular disease, which makes that null the one published result bearing on lactoferrin taken by a person with no diagnosed skin condition. It was recorded in the trial that gave lactoferrin by itself, over the same twelve weeks in which the acne outcomes moved, and it did not change.

Neither systematic review reports a trial of lactoferrin against skin aging, wrinkling, firmness or pigmentation, and the searches behind this page found none either. So the claim about acne and the claim about skin in general do not rest on the same evidence, and only one of them rests on any.

Where the ingredients were bundled

Chan and colleagues ran the largest acne trial in which lactoferrin was compared against a placebo. One hundred and sixty-eight people aged 13 to 40 took a capsule of lactoferrin with vitamin E and zinc, or placebo, twice a day for three months, double-blind, with 164 completing per protocol. Total lesions fell by a median 28.5% against placebo at week 10, comedones by 32.5% and inflammatory lesions by 44%, each at P below 0.0001, and no adverse events were recorded.

Its reduction in total lesions is larger than Kim's and it enrolled more than four times as many people. It also cannot be assigned to lactoferrin. Three substances went into one capsule and the placebo contained none of them, so the trial compares the mixture against nothing and has no arm that could separate the three. Its own title describes the intervention as lactoferrin with vitamin E and zinc. The authors list their affiliations as a contract clinical trials company and the research and development division of a pharmaceutical manufacturer, which is stated in the paper rather than uncovered here, and is a reason to read the design closely rather than to discard the numbers.

The 2022 trial in 184 Bulgarian women is bundled further. Every participant applied the same retinoid cream; one group of 61 also took a food supplement containing prebiotic oligosaccharides, zinc, lactoferrin and niacinamide. The supplement group ended with a larger absolute reduction in inflammatory lesions, 7.0 against 5.5, and a larger fall in the physician's global severity score, 1.5 against 1.1. There was no dummy supplement, so participants knew which group they were in, the trial was blinded to the assessor only, and four ingredients were added at once. The paper's last author gives a cosmetic manufacturer's medical department as an affiliation.

The newborn trial carries a problem the others do not. One hundred and fifty term infants delivered by cesarean section were randomized to a formula fortified with probiotics, milk fat globule membrane, nucleotides and 200 mg of lactoferrin per 100 g, to a control formula, or to exclusive breastfeeding, open-label. Eczema was less frequent in the fortified group, at a risk ratio of 0.647. The control formula also contained lactoferrin, at 45 to 50 mg per 100 g, so that comparison is between two doses inside two different mixtures rather than between lactoferrin and none of it. The trial's primary outcome, upper respiratory infection, showed no difference between any of the three groups, and the authors describe the eczema and dyspepsia findings as exploratory and preliminary in their own conclusion. The same difficulty runs through the trials on lactoferrin and gut health, where three of the seven measured outcomes come from feeds containing more than one added ingredient.

Applied to the skin rather than swallowed

Two studies put lactoferrin on skin instead of into a capsule. With Kim's acne trial they are the three in which nothing else active was added.

Saraceno and colleagues treated 30 people with mild to moderate plaque psoriasis for four weeks, 22 of whom completed. Every patient took 100 mg of bovine lactoferrin by mouth. Fifteen also applied a 10% ointment to a target plaque and fifteen a 20% ointment, with the ointment base alone on the matching plaque on the other side of the body. Elevation, redness and scaling improved on the treated lesions against the untreated ones, at P below 0.05, and the stronger ointment did no better than the weaker.

The design puts each patient's own skin on both sides of the comparison, which removes the differences between people that a 30-person trial could not otherwise control. It was open-label, so everyone involved knew which lesion was which. The result that travels furthest is one the authors report in a single line: the oral lactoferrin every patient was taking produced no improvement in the control plaques that received the ointment base. Inside a study reporting a positive topical result, the swallowed protein did nothing to the same disease.

The other topical study treated wounds. Fifty-five patients with diabetic neuropathic foot ulcers took part at seven sites. Nine received open-label gel at three concentrations in the first stage. The second stage randomized 46 patients to a 2.5% gel, an 8.5% gel or placebo, applied twice daily for twelve weeks alongside standard wound care, with the proportion of ulcers shrinking by at least 75% as the primary endpoint. That proportion was 47% on the lower concentration and 53% on the higher, against 25% on placebo. Pooling the two active groups against placebo on an intention-to-treat basis gave P = 0.09.

Several features set what that result can carry. The trial was powered in advance to detect a difference at P below 0.1 rather than the conventional 0.05. It was single-blind. Fifteen patients per active arm makes it a dose-finding study, its stated conclusion is that the gel appears safe and well tolerated, and no phase 3 trial of the gel in this indication has been published since.

The protein in that gel was talactoferrin alfa, a recombinant copy of the human molecule, not the bovine lactoferrin in milk or in supplements. The two adult trials of that same recombinant protein in other diseases both failed, which is set out under human lactoferrin. Nothing on the skin question transfers between the two proteins without being tested, and no trial has compared them on a skin endpoint.

Why the grade is Preliminary

The graded claim here is narrower than the page title: acne. It is the only skin condition with more than one trial of lactoferrin behind it, and those three trials point the same way.

Three concordant randomized trials would ordinarily read as better than preliminary. The subtraction is what holds the grade down. Remove the trial that added zinc and vitamin E to the same capsule, remove the trial that added a four-ingredient supplement on top of a retinoid cream, and what remains behind the acne claim is one double-blind trial of 36 people over twelve weeks, with no replication since 2010. The grade describes what survives the subtraction rather than the number of records in the search result.

This is a different shape from the two Insufficient grades on neighboring pages. There, pooled analyses of thousands of participants either disagreed with each other or agreed about a population that was not the one in the claim. Here no pooled analysis exists, because seven studies spread across acne, psoriasis, ulcers, dermatitis and infant eczema have nothing to pool, and the one trial that isolated the protein points toward the claim rather than away from it. Early human data, small and short, is what Preliminary is for.

Two findings on this page sit outside the graded claim and should not be read into it. The psoriasis study found that the oral lactoferrin all of its patients were taking did nothing to their control plaques, and the acne trial that measured hydration and pH found no change in either. Neither is a verdict on acne, and both are measurements rather than absences of evidence, which is why they are stated here plainly.

Plenty of the laboratory work behind the claim is sound. Lactoferrin binds iron that bacteria need and part of the molecule disrupts bacterial membranes directly. Both acne trials open by citing that antibacterial and anti-inflammatory culture work as their rationale, and lactoferrin carries the full ledger of graded claims with the scale that produced them. What the 2026 review says about that work is that it has not yet been followed by the trials it implies: the dermatology evidence remains mainly in vitro and animal, and the same gap between culture and patient appears on lactoferrin and antibacterial action. Doses in the trials above ran from 200 mg a day by mouth to an 8.5% topical gel, and lactoferrin side effects reports what these and other trials logged. The hub on lactoferrin benefits groups every claim by its grade.